ID   YCC-3/R
AC   CVCL_9658
DR   cancercelllines; CVCL_9658
DR   Wikidata; Q54995336
RX   PubMed=20661724;
CC   Population: Korean.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9657 ! YCC-3
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 16
//
RX   PubMed=20661724; DOI=10.1007/s12272-010-0720-5;
RA   Le T.V.T., Seo Y., Ryu C.J., Lee H.R., Park H.-J.;
RT   "Increased expression of p27 is associated with the cisplatin
RT   resistance in gastric cancer cell line YCC-3.";
RL   Arch. Pharm. Res. 33:1127-1132(2010).
//